Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.56 |
| ▸ | PREP | P48147 | 3/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8209315 | 1.00 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30055 | 1.00 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8791674 | 0.98 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8790416 | 0.97 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL9096188 | 0.94 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30053426 | 0.90 | NPSR1 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30877842 | 0.90 | NPSR1 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8208547 | 0.90 | NPSR1 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8208549 | 0.90 | NPSR1 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30053580 | 0.90 | NPSR1 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2609078-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025164-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
| CN-1142140-C | Acylation method | ������ҩ������˾ | 2004-03-17 | — | — | CN | disclosed |
| EP-0666858-B1 | 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT 1) AGONISTS | PFIZER (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1094064-A1 | 5-arylindolederivatives and their use as serotonin(5-ht1)agonists | PFIZER INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| CN-1290697-A | Acylation method | PFIZER (US) | 2001-04-11 | — | — | CN | disclosed |
| US-6100291-A | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-08-08 | — | — | US | disclosed |
| US-5886008-A | 5-arylindole derivatives | PFIZER INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | GABRA1 2169/4885GABRG2 2437/4885GABRB3 2092/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | GABRA1 2071/4885GABRG2 2490/4885GABRB3 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.